A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00369161 |
Recruitment Status
:
Completed
First Posted
: August 29, 2006
Results First Posted
: January 19, 2011
Last Update Posted
: March 3, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Renal Transplantation | Drug: Everolimus (RAD001) Drug: Tacrolimus Drug: Basiliximab Drug: Corticosteroids | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 228 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With IL-2 Receptor Antagonist, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients |
Study Start Date : | June 2006 |
Actual Primary Completion Date : | December 2008 |
Actual Study Completion Date : | December 2008 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Very low dose tacrolimus
The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 1.5 and 3 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
|
Drug: Everolimus (RAD001) Drug: Tacrolimus Drug: Basiliximab Drug: Corticosteroids |
Active Comparator: Low dose tacrolimus
The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 4 and 7 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
|
Drug: Everolimus (RAD001) Drug: Tacrolimus Drug: Basiliximab Drug: Corticosteroids |
- Renal Function Assessed by Calculated Glomerular Filtration Rate (cGFR) [ Time Frame: 12 months post -transplant ]
Renal function was assessed by calculated glomerular filtration rate (cGFR) using Modification of Diet in Renal Disease (MDRD)formula.
GFR [mL/min/1.73m^2] = 186.3*(C-1.154)*(A-0.203)*G*R, where:
- C is the serum concentration of creatinine [mg/dL],
- A is patient age at sample collection date [years],
- G=0.742 when gender is female, otherwise G=1,
- R=1.21 when race is black, otherwise R=1
- Number of Participants With Incidence of Biopsy-proven Acute Rejection (BPAR) [ Time Frame: from Month 4 through to Month 12 ]Biopsy-proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy (performed by the local pathologist). For all clinically suspected rejection episodes a graft core biopsy must have been performed before or within a 24 hour period from the initiation of anti-rejection therapy.
- Percentage of Participants With Efficacy Failure [ Time Frame: Month 12 ]Efficacy failure was a composite of BPAR, graft loss, death or lost to follow-up. BPAR was defined as a clinically suspected acute rejection confirmed by biopsy (performed by the local pathologist). For all clinically suspected rejection episodes a graft core biopsy must have been performed before or within a 24 hour period from the initiation of anti-rejection therapy. An allograft was presumed to be lost on the day a patient started dialysis and was unable to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, the day of nephrectomy was the day of graft loss.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria
- Male or female of 18-65 years old
- Patient who has received a primary kidney transplant from a cadaveric, living unrelated or non-human leucocyte antigen (HLA) identical living related donor
- Recipient of a kidney with a cold ischemia time (CIT) < 30 hours
- Recipient of a kidney from a donor 10-65 years old
- Patient able to receive the first dose of tacrolimus within 24 hours from graft reperfusion
- Female capable of becoming pregnant must have a negative pregnancy test and is required to practice a medically approved method of birth control for the duration of the study and for a period of three months following discontinuation of investigational drug
- Patient willing and capable of giving written informed consent for study participation and able to participate in the study for 12 months
Exclusion criteria
- Patient who has previously received an organ transplant
- Recipient of multiple organ transplants
- Recipient of a kidney transplant from a non heart-beating donor
- Recipient of donor specific transfusions
- Recipient of A-B-O incompatible transplant or T-cell cross-match positive transplant
- Patient with current Panel Reactive Antibodies (PRA) level ≥ 50%
- Recipient of a kidney from a donor who tests positive for hepatitis B surface antigen or hepatitis C antibodies
- Patient who is human immunodeficiency virus (HIV) positive
- Patient who has a positive hepatitis C serology or who is hepatitis B surface antigen positive with evidence of liver injury as indicated by aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels ≥2.5 times upper limit of normal (UNL). Viral serology results obtained within 6 months prior to the administration of the first dose of Certican™ are acceptable
- Patient with severe hypercholesterolemia (350 mg/dL, 9.1 mmoL/dL) or hypertriglyceridemia ( 500 mg/dL, 5.6 mmoL/L)
- Patient with white blood cell (WBC) count 3,000/mm3 or with platelet count 75,000/mm3
- Patient with any severe allergy requiring acute (within 4 weeks of baseline) or chronic treatment, or with hypersensitivity to drugs similar to Certican (e.g., macrolides)
- Patient who has been treated with an immunosuppressive drug or an investigational drug within 4 weeks prior to the administration of the first dose of Certican
- Patient with uncontrolled infection
- Patient with any surgical or medical condition, other than the current transplant, which in the opinion of the investigator, precludes enrollment in this trial
- Patient with a known malignancy or a history of malignancy within last 5 years other than successfully treated localized basal or squamous cell carcinoma of the skin
- Abnormal physical or laboratory findings of clinical significance within 2 weeks prior to the administration of the first dose of Certican™ which at investigator's discretion would interfere with the objectives of the study
- Breast feeding women
- Patient with symptoms of significant somatic or mental illness or with unresolved history of drug or alcohol abuse
- Patient unable to cooperate or communicate with the investigator

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00369161
Switzerland | |
Novartis | |
Basel, Switzerland |
Study Director: | Novartis | Novartis |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | External Affairs, Novartis Pharmaceticals |
ClinicalTrials.gov Identifier: | NCT00369161 History of Changes |
Other Study ID Numbers: |
CRAD001A2426 |
First Posted: | August 29, 2006 Key Record Dates |
Results First Posted: | January 19, 2011 |
Last Update Posted: | March 3, 2017 |
Last Verified: | February 2017 |
Additional relevant MeSH terms:
Tacrolimus Everolimus Sirolimus Basiliximab Antibodies, Monoclonal Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
Calcineurin Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antifungal Agents |